The anti-neprilysin market is focused on the development of neprilysin inhibitors that can be used for the treatment of heart failure. Neprilysin is an enzyme that breaks down natriuretic peptides which help relax blood vessels and regulate blood pressure and volume in the body. Inhibiting this enzyme helps increase levels of natriuretic peptides and improves cardiac function. Key players in this market are developing novel neprilysin inhibitors to overcome challenges associated with first-generation drugs and make treatment more effective.
The Global anti-neprilysin market is estimated to be valued at US$ 1,263.3 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.
Key Takeaways
Key players operating in the anti-neprilysin market are BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, Oceanic Pharmachem Pvt. Ltd. The development of second-generation neprilysin inhibitors with improved safety profiles represents a major opportunity in this market. Technological advancements are focused on developing orally bioavailable neprilysin inhibitors with reduced risk of side effects like hypotension and angioedema seen with first-generation drugs.
Key opportunities in the market include development of neprilysin inhibitors for indications beyond heart failure like diabetes, hypertension and chronic kidney disease. The approval of sacubitril-valsartan (Entresto) in 2014 validated neprilysin inhibition as a therapeutic approach and has driven further R&D in this field.
Technological advancements include development of small molecule neprilysin inhibitors and neprilysin-neutral endopeptidase dual inhibitors with better selectivity, solubility and pharmacokinetic profiles. Researchers are also exploring neprilysin gene therapy and recombinant human neprilysin approaches to develop novel treatment options.
Market drivers
The growing geriatric population prone to developing heart failure is a key driver for the anti-neprilysin market. It is estimated that by 2050, over 20% of the global population will be aged over 60 years. Also, rising incidence of conditions like hypertension and diabetes which can lead to heart failure will propel the need for more effective drugs targeting neprilysin. The lack of effective alternatives beyond ACE inhibitors and ARBs also creates opportunities for neprilysin inhibitors to capture a bigger share of the heart failure treatment market.
Current challenges in Anti-Neprilysin market
The Anti-Neprilysin market is currently facing several challenges which are restricting its growth prospects. Patent cliffs of blockbuster drugs, cost of R&D activities and stringent regulations for drug approval are some of the major hurdles being faced by market players. Further, lack of awareness about Neprilysin inhibition as a therapeutic approach and preferred usage of existing heart failure drugs are impeding the demand for anti-Neprilysin drugs. However, ongoing clinical trials evaluating novel therapeutic candidates and initiatives to improve access are expected to help overcome these challenges in the coming years.
SWOT Analysis
Strength: Presence of strong pipeline and ongoing clinical trials evaluating safety and efficacy of new molecule.
Weakness: High attrition rates during drug development and stringent regulatory norms.
Opportunity: Increasing prevalence of heart failure and lack of effective treatment options.
Threats: Patent expiries of major drugs, preference for existing therapeutic classes and pricing pressure.
The United States represents the most lucrative market for Anti-Neprilysin, accounting for over 35% of global revenue. This is attributed to the presence of advanced healthcare infrastructure, rising healthcare spending and growing heart failure burden in the country. Europe is also among the prominent regional markets driven by supportive government initiatives for research.
Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing patient pool, improving access to diagnosis and treatment, and rising healthcare expenditure in countries like China and India. Moreover, growing collaborations between regional and international market players are helping increase product availability.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/